The Centre for Commercialization of Regenerative Medicine (CCRM) Australia again partners with local and international venture capital firms to hold a second National Regenerative Medicine SuperPitch. The SuperPitch offers expertise and investment funding for translation and commercialisation of Australian projects related to regenerative medicine.
Regenerative medicine includes technologies and therapies that regenerate or replace injured, diseased, or defective cells, tissues, or organs to restore or establish function and structure. Submissions may relate to cell therapies, gene therapies, combination therapies, gene editing tools, enabling technologies such as vector production, automated analytical assays, biosensors, novel media, and other projects related to regenerative medicine in a wide range of therapeutic area.
The National Regenerative Medicine SuperPitch provides an opportunity for companies and researchers to showcase their technologies or ideas. Expert feedback, commercialisation support from CCRM Australia and (for suitable projects) further development funding will be made available. The participation of partners with expertise in various specialties and lifecycle stages empowers the SuperPitch to streamline progress from proof of concept through to clinical trials.
Shortlisted applicants will be invited to provide a thirty-minute presentation, which must include objective data on their technologies to a panel of regenerative medicine, venture capital and commercialisation experts from the consortia. A discussion period will extend the total presentation period to 45 minutes.
The second CCRM Australia National Regenerative Medicine SuperPitch will be held online on the morning of the 4th of December 2020. The video conferencing application Zoom will be used for all participants.
Applications via expression of interest close 5 pm AEDT Friday, 23rd October 2020
Shortlisted applicants will be informed during the week commencing 9th November 2020
SuperPitch Event: Friday, 4th December 2020
Please refer to the FAQ’s, or contact Dr Jack Lambshead at email@example.com for more information.